Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Ross L. Levine(Brigham and Women's Hospital), Martha Wadleigh(Harvard University), Jan Cools(Vlaams Instituut voor Biotechnologie), Benjamin L. Ebert(Broad Institute), Gerlinde Wernig(Brigham and Women's Hospital), Brian J.P. Huntly(Brigham and Women's Hospital), Titus J. Boggon(Dana-Farber Cancer Institute), Iwona Włodarska(Vlaams Instituut voor Biotechnologie), Jennifer Clark(Brigham and Women's Hospital), Sandra Moore(Brigham and Women's Hospital), Jennifer Adelsperger(Brigham and Women's Hospital), Sumin Koo(Brigham and Women's Hospital), Jeffrey C. Lee(Broad Institute), Stacey Gabriel(Broad Institute), Thomas Mercher(Brigham and Women's Hospital), Alan D. D’Andrea(Dana-Farber Cancer Institute), Stefan Fröhling(Brigham and Women's Hospital), Konstanze Döhner(University Hospital Ulm), Peter Marynen(Vlaams Instituut voor Biotechnologie), Peter Vandenberghe(Vlaams Instituut voor Biotechnologie), Ruben A. Mesa(Mayo Clinic), Ayalew Tefferi(Mayo Clinic), James D. Griffin(Harvard University), Michael J. Eck(Dana-Farber Cancer Institute), William R. Sellers(Broad Institute), Matthew Meyerson(Broad Institute), Todd R. Golub(Broad Institute), Stephanie J. Lee(Harvard University), D. Gary Gilliland(Brigham and Women's Hospital)
Cited by 2,989Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis